These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 38616444)
1. Plasma Thioredoxin Reductase as a Potential Diagnostic Biomarker for Breast Cancer. Hu Y; Zhu Y; Shi J; Wei X; Tang C; Guan X; Zhang W Clin Breast Cancer; 2024 Aug; 24(6):e464-e473.e3. PubMed ID: 38616444 [TBL] [Abstract][Full Text] [Related]
2. Plasma Thioredoxin Reductase as a Potential Biomarker for Gynecologic Cancer. Zhu Y; Hu Y; Shi J; Wei X; Song Y; Tang C; Zhang W Technol Cancer Res Treat; 2023; 22():15330338231184995. PubMed ID: 37365925 [TBL] [Abstract][Full Text] [Related]
3. Thioredoxin reductase as a novel biomarker for the diagnosis and efficacy prediction of gastrointestinal malignancy: a large-scale, retrospective study. Hu Y; Zhu Y; Nie W; Shi J; Wei X; Tang C; Zhang W Int J Clin Oncol; 2023 Jul; 28(7):880-892. PubMed ID: 37142881 [TBL] [Abstract][Full Text] [Related]
4. Plasma activity of Thioredoxin Reductase as a Novel Biomarker in Gastric Cancer. Peng W; Zhou Z; Zhong Y; Sun Y; Wang Y; Zhu Z; Jiao W; Bai M; Sun J; Lu J; Yin H Sci Rep; 2019 Dec; 9(1):19084. PubMed ID: 31836775 [TBL] [Abstract][Full Text] [Related]
5. Thioredoxin Reductase as a Novel and Efficient Plasma Biomarker for the Detection of Non-Small Cell Lung Cancer: a Large-scale, Multicenter study. Ye S; Chen X; Yao Y; Li Y; Sun R; Zeng H; Shu Y; Yin H Sci Rep; 2019 Feb; 9(1):2652. PubMed ID: 30804354 [TBL] [Abstract][Full Text] [Related]
6. Plasma thioredoxin reductase: a potential diagnostic biomarker for gastric cancer. Zhu Y; Hu Y; Zhu X; Zhang J; Yuwen D; Wei X; Tang C; Zhang W Carcinogenesis; 2022 Sep; 43(8):736-745. PubMed ID: 35709525 [TBL] [Abstract][Full Text] [Related]
7. Clinical application of thioredoxin reductase as a novel biomarker in liver cancer. Wu X; Wang Q; Lu Y; Zhang J; Yin H; Yi Y Sci Rep; 2021 Mar; 11(1):6069. PubMed ID: 33727662 [TBL] [Abstract][Full Text] [Related]
8. Thioredoxin reductase: a novel, independent prognostic marker in patients with hepatocellular carcinoma. Li C; Peng Y; Mao B; Qian K Oncotarget; 2015 Jul; 6(19):17792-804. PubMed ID: 25970775 [TBL] [Abstract][Full Text] [Related]
9. Tissue and plasma thioredoxin reductase expressions in patients with glioblastoma multiforme. Kemerdere R; Kacira T; Hanimoglu H; Kucur M; Tanriverdi T; Canbaz B J Neurol Surg A Cent Eur Neurosurg; 2013 Jul; 74(4):234-8. PubMed ID: 23512591 [TBL] [Abstract][Full Text] [Related]
10. Plasma and Synovial Fluid TrxR Levels are Correlated With Disease Risk and Severity in Patients With Rheumatoid Arthritis. Xie Z; Sun J; Li H; Shao T; Wang D; Zheng Q; Wen C Medicine (Baltimore); 2016 Feb; 95(6):e2543. PubMed ID: 26871773 [TBL] [Abstract][Full Text] [Related]
11. [Correlation of plasma thioredoxin reductase activity to growth of H22 hepatocellular carcinoma xenografts in Kunming mice]. Tan Q; Ren XY; Li J; Wang F; Deng SJ; Zeng HH Ai Zheng; 2009 May; 28(5):472-7. PubMed ID: 19624873 [TBL] [Abstract][Full Text] [Related]
12. Serum thioredoxin reductase is highly increased in mice with hepatocellular carcinoma and its activity is restrained by several mechanisms. Zhang L; Cheng Q; Zhang L; Wang Y; Merrill GF; Ilani T; Fass D; Arnér ESJ; Zhang J Free Radic Biol Med; 2016 Oct; 99():426-435. PubMed ID: 27581528 [TBL] [Abstract][Full Text] [Related]
13. High redox thioredoxin but low thioredoxin reductase activities in the serum of patients with rheumatoid arthritis. Lemarechal H; Allanore Y; Chenevier-Gobeaux C; Ekindjian OG; Kahan A; Borderie D Clin Chim Acta; 2006 May; 367(1-2):156-61. PubMed ID: 16458876 [TBL] [Abstract][Full Text] [Related]
14. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Kohler C; Radpour R; Barekati Z; Asadollahi R; Bitzer J; Wight E; Bürki N; Diesch C; Holzgreve W; Zhong XY Mol Cancer; 2009 Nov; 8():105. PubMed ID: 19922604 [TBL] [Abstract][Full Text] [Related]
15. Thioredoxin reductase gene expression and activity among human T-cell lymphotropic virus type 1-infected patients. Yaghoubi N; Youssefi M; Hashemy SI; Rafat Panah H; Mashkani BA; Zahedi Avval F J Med Virol; 2019 May; 91(5):865-871. PubMed ID: 30489643 [TBL] [Abstract][Full Text] [Related]
16. Serum Human Epididymis Protein-4 (HE4) - A novel Approach to Differentiate Malignant Frombenign Breast Tumors. Sai Baba KSS; Rehman MA; Pradeep Kumar J; Fatima M; Raju GSN; Uppin SG; Mohammed N Asian Pac J Cancer Prev; 2021 Aug; 22(8):2509-2507. PubMed ID: 34452565 [TBL] [Abstract][Full Text] [Related]
17. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses. Park BJ; Cha MK; Kim IH BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391 [TBL] [Abstract][Full Text] [Related]
18. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy. Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747 [TBL] [Abstract][Full Text] [Related]
19. Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Kahlos K; Soini Y; Säily M; Koistinen P; Kakko S; Pääkkö P; Holmgren A; Kinnula VL Int J Cancer; 2001 May; 95(3):198-204. PubMed ID: 11307155 [TBL] [Abstract][Full Text] [Related]
20. Large intergenic non-coding RNA-ROR as a potential biomarker for the diagnosis and dynamic monitoring of breast cancer. Zhao T; Wu L; Li X; Dai H; Zhang Z Cancer Biomark; 2017 Aug; 20(2):165-173. PubMed ID: 28869448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]